进展期胆囊癌转化治疗研究进展  

Advances in conversion therapy for progressive gallbladder carcinoma

作　　者：陶生威 尹大龙 TAO Sheng-wei;YIN Da-long(Department of Hepatobiliary Surgery and Centre for Leading Medicine and Advanced Technologies of IHM,the First Affiliated Hospital of USTC,University of Science and Technology of China,Hefei 230001,China)

机构地区：[1]中国科学技术大学附属第一医院(安徽省立医院)先导医学与前沿技术研究所肝胆外科,安徽合肥230036

出　　处：《中国实用外科杂志》2023年第11期1309-1314,共6页Chinese Journal of Practical Surgery

基　　金：国家卫生健康委医院管理研究所重点项目(No.YLZLXZ22K004)。

摘　　要：进展期胆囊癌的转化治疗尚处于起步阶段。以吉西他滨联合顺铂作为基础化疗方案的不同组合在进展期胆囊癌的转化治疗中表现出较高的客观缓解率,为一部分病人创造了根治性切除的手术机会。针对不同突变靶点的靶向治疗和针对程序性死亡因子-1的免疫检查点抑制剂为代表的免疫治疗目前在进展期胆囊癌的转化治疗中也展现出巨大潜力。在未来,针对具体突变靶点个性化制定综合转化治疗方案以及结合人工智能对胆囊癌进行早诊早治、治疗方案选择,可能将进一步提升进展期胆囊癌病人转化成功率。Conversion therapy for advanced gallbladder cancer is still at the start stage.Different combinations of gemcitabine combined with cisplatin as the basic chemotherapy regimen have shown high objective response rates in the conversion therapy of advanced gallbladder cancer,creating surgical opportunities for curative resection for patients.Targeted therapies against different mutation targets and immunotherapy represented by immune checkpoint inhibitors against programmed death receptor-1 are also showing immense potential in the conversion therapy of advanced gallbladder cancer.In the future,individualized treatment for specific mutations targets and the combination of artificial intelligence for early diagnosis and treatment may further improve the conversion rate of patients with advanced gallbladder cancer.

关 键 词：胆囊癌 进展期 转化治疗 系统化疗 

分 类 号：R6[医药卫生—外科学]